Eli Lilly Cancer Drug fails during clinical trial
Eli Lilly and Co has reported failure of its experimental lung cancer drug for late-stage trial. During the current trial, Lilly was testing Verzenio in patients with advanced non-small cell lung cancer with mutation of the KRAS gene. The company has shared limited data about the drug trial and informed that the overall survival rate among patients in the trial didn’t improve. Eli Lilly has suffered two other setbacks earlier this year.
The company faced U.S. FDA rejection rheumatoid arthritis drug in April. The company has witnessed decline in stock valuation as well. After the new, Lilly stock was down by nearly 3 percent during early trading session. With an aim to cut costs, Lilly reduced its workforce by 8 percent last month. The company informed that reduction in workforce would save $500 million each year.
Lilly informed, “Verzenio, however, showed some evidence of improvement in the secondary goals such as progression-free survival in patients and overall response rate.”
Verzenio has been approved by FDA for advanced stage breast cancer last month.
In November last year, the company dropped an experimental Alzheimer’s treatment after the results weren’t encouraging.
A Translational Pharmaceutics stage, Quotient Clinical connoting its new personality to Quotient Sciences resulting acquirements of SeaView Research, QS Pharma, and Co-Formulate.
Intelligent and connected vehicles are turning into the Chinese business' specialty in the new automotive era. TuSimple Inc. reveals demonstrates minds-off automated driving using two modified trucks in Shanghai.
Well-known for its technology innovation, China region unveiled the first picture of the hypersonic strike airplane that is being created to convey atomic warheads through U.S. rocket protections. The pictures of four distinct rockets that U.S.
New York-based broad communications partnership, Time Inc. uncovered another advanced stage called Time Inc. Latino. Through its new computerized stage Time conveys exceptional access to the U.S. Hispanic group of viewers.
Chinese Multinational Telecommunication Equipment company, ZTE corporation officially released TECS 6.0. The company released the new generation cloud platform at the OpenStack Summit Sydney.
German-based, multinational open-source software company SUSE combines Cloud Foundry and Kubernetes to accelerate application delivery, which also helps to increase business agility.